IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Mallinckrodt PLC and Encourages Investors with…

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Mallinckrodt PLC and Encourages Investors with Losses to Contact the Firm

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Mallinckrodt PLC ("Mallinckrodt" or the "Company") (NYSE: MNK). Investors who purchased or otherwise acquired Mallinckrodt shares between November 25, 2014 and January 18, 2017 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline (see also Khang & Khang LLP).

If you purchased shares of Mallinckrodt during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, during the Class Period, Mallinckrodt and its Chief Executive Officer, Mark Trudeau, released several false and misleading statements and failed to disclose material adverse facts about the sustainability of the Company's monopolistic HP Acthar Gel ("Acthar") profits and the exposure of Acthar to reimbursement rates by Medicare and Medicaid.

In particular, Defendants rendered false and/or misleading statements and/or failed to disclose that Acthar's monopoly status as the sole FDA-approved adrenocorticotropic hormone preparation was the result of unlawful anticompetitive practices and failed to reveal that its heightened reliance on Medicare and Medicaid meant that Mallinckrodt's monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.

When this information was released to the public, the value of Mallinckrodt fell, causing investors harm.

If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions. View source version on businesswire.com: http://www.businesswire.com/news/home/20170126005908/en/

Keywords for this news article include: Medicaid, Medicare, Legal Issues, Health Policy, Khang & Khang LLP.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC